saplin

Nippon India Pharma Fund

Nippon India Pharma Fund (Direct, Growth): saplin Score 6.6/10 (Neutral) among 14 Sectoral/Thematic funds. 3Y return 18.7% a year vs 21.9% category median, expense ratio 0.98%. Better downside protection than most peers, but uneven returns. NAV ₹663.12 on 11 Nov 2026.

Loading the full analysis…

Questions about Nippon India Pharma Fund

What is the expense ratio of Nippon India Pharma Fund?

The Direct plan's total expense ratio is 0.98% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages Nippon India Pharma Fund?

Sailesh Raj Bhan (since June 2004).

What are the top holdings of Nippon India Pharma Fund?

Sun Pharmaceutical Industries 11.55%, Divi's Laboratories 6.73%, Cipla 6.21%, Lupin 6.16%, Dr. Reddy's Laboratories 6.13% of the portfolio, as of 31 Oct 2026.

What returns has Nippon India Pharma Fund given?

1 year: 16.2% (category median 21.9%); 3 years: 18.7% a year (category median 21.9%); 5 years: 15.4% a year (category median 16.8%). Past returns do not predict future ones.

How big is Nippon India Pharma Fund?

About ₹9,272 cr (AMFI's average for the latest quarter).

How does Nippon India Pharma Fund score?

6.6 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on Nippon India Pharma